UPCC 01826 FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer

Study of Sofetabart Mipitecan for Ovarian Cancer

Enrolling By Invitation
99 years or below
All
Phase N/A
5 participants needed
1 Location

Brief description of study

This is a clinical study that has two parts. It is testing a potential new medicine called Sofetabart Mipitecan (LY4170156) for people with certain types of ovarian, peritoneal, and fallopian tube cancers. Part A looks at participants whose cancer no longer responds to platinum-based treatments (a type of chemotherapy). Part B looks at participants whose cancer still responds to platinum-based treatments. The researchers want to find out if Sofetabart Mipitecan works better than the usual treatments that doctors use now and to better understand how safe it is. Each participant's time in the study will depend on how they respond to the treatment.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

This study investigates ovarian cancer. The purpose of this study is to compare the investigational medication, Sofetabart Mipitecan, with standard chemotherapy or other treatments for ovarian cancer.

The study evaluates the effectiveness and safety of Sofetabart Mipitecan in treating ovarian cancer compared to current standard treatments.

  • Who can participate: Participants must be adults diagnosed with ovarian cancer. Additional eligibility criteria are to be determined (TBD).
  • Study details: Participants will receive either the investigational medication or standard treatment options. The study will assess how well Sofetabart Mipitecan works in comparison to other treatments.
Updated on 03 Aug 2026. Study ID: 26-6545
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator